GSK-3β-IN-28

GSK-3β inhibitor 28 is selective and non-competitivea glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 14.82 nM. GSK-3β inhibitor 28 can upregulate the expression level of phosphorylated GSK-3β and downregulate the expression of p-NF-κB, P65, C-myc and Cyclin D1. GSK-3β inhibitor 28 can induce cells apoptosis, G1 phase arrest and inhibit migration. GSK-3β inhibitor 28 can be used for the research of cancer, such as colorectal cancer[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; c-Myc; GSK-3; NF-κB

Related Pathways

Apoptosis; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt

Field of Research

Cancer

Smiles

O=C(N1CCC2=CC=CC=C2)N(C3=CC4=C(N(C(C=C)=O)C=C4Cl)C=C3)SC1=O

Molecular Formula

C21H16ClN3O3S

Molecular Weight

425.89

References & Citations

[1]Xu J, et al. Design, synthesis, and biological evaluation of novel GSK-3β covalent inhibitors for cancer treatment. Bioorg Chem. 2025 Sep;164:108856.